neoadjuvant chemotherapy

You have access
Simple Cancer Stem Cell Markers Predict Neoadjuvant Chemotherapy Resistance of Esophageal Squamous Cell Carcinoma
KYOSUKE AGAWA, KIMIHIRO YAMASHITA, AKIO NAKAGAWA, KOUTA YAMADA, AKIHIRO WATANABE, JUNKO MUKOHYAMA, MASAFUMI SAITO, MITSUGU FUJITA, GOSUKE TAKIGUCHI, NAOKI URAKAWA, HIROSHI HASEGAWA, SHINGO KANAJI, TAKERU MATSUDA, TARO OSHIKIRI, TETSU NAKAMURA, SATOSHI SUZUKI and YOSHIHIRO KAKEJI

Anticancer Research August 2021, 41 (8) 4117-4126; DOI: https://doi.org/10.21873/anticanres.15214
You have access
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers
EIJI KONDO, RYO NIMURA, SHINTARO MAKI, MICHIKO KANEDA, MASAFUMI NII, KENTA YOSHIDA, TSUTOMU TABATA and TOMOAKI IKEDA

Anticancer Research August 2021, 41 (8) 4157-4161; DOI: https://doi.org/10.21873/anticanres.15219
You have access
Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer
MISATO OGINO, TAKAAKI FUJII, YUKIO KOIBUCHI, YUKO NAKAZAWA, DAISUKE TAKATA and KEN SHIRABE

Anticancer Research August 2021, 41 (8) 3899-3904; DOI: https://doi.org/10.21873/anticanres.15185
You have access
Total Mesometrial Resection With (Neo)Adjuvant Chemotherapy in Locally Advanced Cervical Cancer: A Tumor Response Score
MATTHIAS KIESEL, STEPHANIE SAUER, SANJA LÖB, SASKIA L. HERBERT, ACHIM WÖCKEL and CHRISTINE WULFF

Anticancer Research July 2021, 41 (7) 3543-3560; DOI: https://doi.org/10.21873/anticanres.15142
You have access
Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival
PAOLO ORSARIA, ANTONELLA GRASSO, EDY IPPOLITO, FRANCESCO PANTANO, MATTEO SAMMARRA, CARLO ALTOMARE, BARBARA CAGLI, FABIO COSTA, GIUSEPPE PERRONE, GEORGETA SOPONARU, LORENZA CAGGIATI, GIANLUCA VANNI, ORESTE CLAUDIO BUONOMO and VITTORIO ALTOMARE

Anticancer Research May 2021, 41 (5) 2697-2709; DOI: https://doi.org/10.21873/anticanres.15051
You have access
Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma
HEE JUNG KWON, SANG YONG SONG and HYUN-SOO KIM

Anticancer Research March 2021, 41 (3) 1579-1586; DOI: https://doi.org/10.21873/anticanres.14918
You have access
Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study
AKIMITSU YAMADA, KYOKO NAKAZAWA, KOHEI AKAZAWA, KAZUTAKA NARUI, ITARU ENDO, YOSHIE HASEGAWA, NORIO KOHNO, TAKASHI ISHIKAWA and THE JONIE STUDY GROUP

Anticancer Research February 2021, 41 (2) 1063-1068; DOI: https://doi.org/10.21873/anticanres.14863
You have access
Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response
GIAMPAOLO DI MARTINO, ANDREA ALBERTO LISSONI, DEBORA FERRARI, MARIA LETIZIA DI MEO, STEFANIA COSIO, ANGIOLO GADDUCCI and FABIO LANDONI

Anticancer Research January 2021, 41 (1) 497-502; DOI: https://doi.org/10.21873/anticanres.14800
You have access
Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer
DEANNA HUFFMAN, RODNEY WEGNER, AMJAD JALIL, THOMAS KRIVAK and EIRWEN MILLER

Anticancer Research November 2020, 40 (11) 6003-6008; DOI: https://doi.org/10.21873/anticanres.14621
You have access
Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer – A Single-institution Experience
WOJCIECH MAJEWSKI, JAROSLAW NIECKULA, TOMASZ DWORZECKI and LESZEK MISZCZYK

Anticancer Research October 2020, 40 (10) 5861-5868; DOI: https://doi.org/10.21873/anticanres.14605

Main menu

User menu

Search

neoadjuvant chemotherapy

Pages